$153 Million is the total value of Memorial Sloan Kettering Cancer Center's 4 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
RPRX | ROYALTY PHARMA PLC | $109,880,000 | -6.0% | 2,680,644 | 0.0% | 71.84% | -0.3% | |
GDX | VANECK VECTORS ETF TRgold miners etf | $25,094,000 | +4.6% | 738,500 | 0.0% | 16.41% | +10.9% | |
ORIC | ORIC PHARMACEUTICALS INC | $10,654,000 | -27.8% | 602,272 | 0.0% | 6.96% | -23.4% | |
YMAB | Y-MABS THERAPEUTICS INC | $7,332,000 | +11.8% | 216,916 | 0.0% | 4.79% | +18.6% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-16
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
VANECK VECTORS ETF TR | 12 | Q3 2023 | 80.9% |
ORIC PHARMACEUTICALS INC | 12 | Q3 2023 | 14.8% |
Y-MABS THERAPEUTICS INC | 12 | Q3 2023 | 9.6% |
CARIBOU BIOSCIENCES INC | 8 | Q2 2023 | 19.5% |
ILLUMINA INC | 8 | Q2 2023 | 4.4% |
ROYALTY PHARMA PLC | 6 | Q1 2022 | 75.6% |
View Memorial Sloan Kettering Cancer Center's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Y-mAbs Therapeutics, Inc. | February 14, 2020 | 257,517 | 0.6% |
Actinium Pharmaceuticals, Inc. | February 13, 2018 | 1,230,954 | 1.5% |
Cactus Ventures, Inc. | January 18, 2013 | 5,702,387 | 34.7% |
View Memorial Sloan Kettering Cancer Center's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2023-11-14 |
13F-HR | 2023-08-14 |
13F-HR | 2023-05-15 |
13F-HR | 2023-02-10 |
13F-HR | 2022-11-14 |
13F-HR | 2022-08-15 |
13F-HR | 2022-05-16 |
13F-HR | 2022-02-14 |
13F-HR | 2021-11-15 |
13F-HR | 2021-08-16 |
View Memorial Sloan Kettering Cancer Center's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.